Nuvation Ebitda from 2010 to 2024

NUVB Stock  USD 2.90  0.01  0.35%   
Nuvation Bio's EBITDA is decreasing over the years with slightly volatile fluctuation. EBITDA is expected to dwindle to about -104.6 M. From 2010 to 2024 Nuvation Bio EBITDA quarterly data regression line had arithmetic mean of (51,824,667) and significance of  0.0005. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-99.6 M
Current Value
-104.6 M
Quarterly Volatility
32.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Nuvation Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nuvation Bio's main balance sheet or income statement drivers, such as Interest Expense of 11.1 M, Depreciation And Amortization of 261.8 K or Selling General Administrative of 22.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.57. Nuvation financial statements analysis is a perfect complement when working with Nuvation Bio Valuation or Volatility modules.
  
Check out the analysis of Nuvation Bio Correlation against competitors.
For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.

Latest Nuvation Bio's Ebitda Growth Pattern

Below is the plot of the Ebitda of Nuvation Bio over the last few years. It is Nuvation Bio's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nuvation Bio's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Nuvation Ebitda Regression Statistics

Arithmetic Mean(51,824,667)
Coefficient Of Variation(63.21)
Mean Deviation27,435,111
Median(32,086,000)
Standard Deviation32,759,449
Sample Variance1073.2T
Range87.4M
R-Value(0.79)
Mean Square Error441T
R-Squared0.62
Significance0.0005
Slope(5,760,418)
Total Sum of Squares15024.5T

Nuvation Ebitda History

2024-104.6 M
2023-99.6 M
2022-119.5 M
2021-89.3 M
2020-43.4 M

About Nuvation Bio Financial Statements

Nuvation Bio stakeholders use historical fundamental indicators, such as Nuvation Bio's Ebitda, to determine how well the company is positioned to perform in the future. Although Nuvation Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Nuvation Bio's assets and liabilities are reflected in the revenues and expenses on Nuvation Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Nuvation Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-99.6 M-104.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Nuvation Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nuvation Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nuvation Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nuvation Bio Stock:
Check out the analysis of Nuvation Bio Correlation against competitors.
For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvation Bio. If investors know Nuvation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.18)
Revenue Per Share
0.009
Return On Assets
(0.14)
Return On Equity
(0.96)
The market value of Nuvation Bio is measured differently than its book value, which is the value of Nuvation that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvation Bio's value that differs from its market value or its book value, called intrinsic value, which is Nuvation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvation Bio's market value can be influenced by many factors that don't directly affect Nuvation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.